A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, Michael J.
Wong, Jeffrey Y. C.
Nordquist, Luke
Szmulewitz, Russell Zelig
Agarwal, Neeraj
Attiyeh, Edward F.
Max, Steven I.
Divgi, Chaitanya R.
Patricia, Daniel
Cao, Yu
Li, Xiang
Yu, Alex
Urtishak, Karen
Lauring, Josh David
Sartor, Oliver
机构：
[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] XCanc Omaha, Omaha, NE USA
[4] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA
[5] Huntsman Canc Inst, Salt Lake City, UT USA
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
    Yu, Evan Y.
    Joshua, Anthony M.
    Shore, Neal D.
    Kramer, Gero
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
  • [42] An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Rathkopf, Dana E.
    Saleh, Mansoor N.
    Tsai, Frank Yung-Chin
    Rosen, Lee S.
    Adams, Bonne J.
    Liu, Lilian
    Theuer, Charles P.
    Freddo, James L.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [43] Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.
    Hussain, Syed A.
    Maroto, Pablo
    Climent, Miguel Angel
    Bianchini, Diletta
    Jones, Robert Hugh
    Lin, Chia-Chi
    Wang, Shian-Shiang
    Dean, Emma
    Crossley, Kate
    Schlieker, Laura
    Bogenrieder, Thomas
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human α? integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
    Heidenreich, A.
    Rawal, S. K.
    Szkarlat, K.
    Bogdanova, N.
    Dirix, L.
    Stenzl, A.
    Welslau, M.
    Wang, G.
    Dawkins, F.
    de Boer, C. J.
    Schrijvers, D.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 329 - 336
  • [45] Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Kelly, W.
    Danila, D.
    Lin, C-C.
    Lee, J-L.
    Matsubara, N.
    Ward, P.
    Armstrong, A. J.
    Pook, D.
    Kim, M.
    Dorff, T.
    Fischer, S.
    Lin, Y-C.
    Horvath, L. G.
    Sumey, C.
    Yang, Z.
    Jurida, G.
    Connarn, J.
    Penny, H.
    Stieglmaier, J.
    Appleman, L. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S953 - S954
  • [46] Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Kelly, W. K.
    Danila, D. C.
    Lin, C-C.
    Lee, J-L.
    Matsubara, N.
    Ward, P. J.
    Armstrong, A. J.
    Pook, D. W.
    Kim, M.
    Dorff, T.
    Fischer, S.
    Lin, Y-C.
    Horvath, L. G.
    Sumey, C.
    Yang, Z.
    Jurida, G.
    Connarn, J.
    Penny, H.
    Stieglmaier, J.
    Appleman, L. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1576 - S1576
  • [47] Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Kelly, William Kevin
    Pook, David William
    Appleman, Leonard Joseph
    Waterhouse, David Michael
    Horvath, Lisa
    Edenfield, William Jeffery
    Matsubara, Nobuaki
    Danila, Daniel Costin
    Aggarwal, Rahul Raja
    Petrylak, Daniel Peter
    Sartor, Oliver A.
    Sumey, Christopher Joseph
    Adra, Nabil
    Armstrong, Andrew J.
    Cheng Fu-Chih
    Stieglmaier, Julia
    Kouros-Mehr, Hosein
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [48] Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Kelly, W. Kevin
    Danila, Daniel Costin
    Edenfield, William Jeffery
    Aggarwal, Rahul Raj
    Petrylak, Daniel Peter
    Sartor, A. Oliver
    Sumey, Christopher Joseph
    Dorff, Tanya B.
    Yu, Evan Y.
    Adra, Nabil
    Waterhouse, David Michael
    Armstrong, Andrew J.
    Horvath, Lisa
    Pook, David William
    Appleman, Leonard Joseph
    Lau, Aubrey
    Salvati, Mark
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Fong, Lawrence
    Beer, Tomasz M.
    Gao, Xin
    Geynisman, Daniel M.
    Burris, Howard A., III
    Strauss, James Fredric
    Courtney, Kevin Dale
    Quinn, David I.
    VanderWeele, David James
    Yaron, Yifah
    Law, Che-Leung
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab plus vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Shore, Neal D.
    De Bono, Johann S.
    Kramer, Gero
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345